Glaukos Corp.

Glaukos Corp.

Glaukos Corp.

Overview
Date Founded

1998

Headquarters

26051 Merit Circle,Suite 103,Laguna Hills, CA 92653

Type of Company

Public

Employees (Worldwide)

653

Industries

Medical Products & Equipment
Medical Support Services
Hospitals & Patient Services

Company Description

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Contact Data
Trying to get in touch with decision makers at Glaukos Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Senior Vice President, General Counsel

Chief Medical Officer

Senior Vice President, Human Resources

Senior Vice President, New Technologies

Senior Vice President, Research & Development

Senior Vice President, Corporate Strategy & Business Development

Vice President, Research & Development, Combination Pharmaceutical Products

Paths to Glaukos Corp.
Potential Connections via
Relationship Science
You
Glaukos Corp.
Owners & Shareholders
Details Hidden

BCM provides investment services to clients on an individual basis, taking into consideration each client's investment objectives, goals, circumstances, and investment needs. When selecting securities and determining the total amount to be purchased or sold, the firm observes the investment policies, limitations and restrictions of the client accounts for which it advises. Their primary approach in evaluating securities is fundamental analysis. The investment strategy employed by BCM generally involves establishing long-term positions. The principal drivers for their sell discipline are: (1) when the fundamentals that spurred the original investment change adversely; (2) the security becomes overvalued, or; (3) it is determined that the security has been an investment mistake. Short sales, margin transactions and options (in all forms) are not utilized.

Details Hidden

Weatherbie Capital employs a fundamental, bottom-up research approach to investing in growth equities. They aim to identify and invest in attractive US small- and mid-cap companies poised for growth. All portfolio managers/analysts are generalists, with coverage across several sectors. Each portfolio manager/analyst has primary responsibility over two to three major growth sectors from which to research companies of potential investment interest. Each member of the investment team is responsible for buy and sells decisions. If a company falls short of our expectations for any non-trivial reason, the firm will sell that stock.

Details Hidden

InterWest Partners focuses on early-stage investments in life sciences and information technology companies. Within the life sciences sector, the firm invests in a range of early-stage opportunities including the funding of preclinical companies with great potential. They also consider investing in or starting new companies around clinical or commercial stage assets. Within the information technology sector, InterWest looks for early-stage companies with near-term ROI-based value propositions. They favor investments in development-stage companies. Investments average $10 million to $15 million over the life of a company. InterWest serves as the lead investor in the majority of their investments.

Recent Transactions
Details Hidden

Glaukos Corp. purchases Avedro, Inc.

Details Hidden

Glaukos Corp. purchases DOSE Medical Corp.

Details Hidden

Glaukos Corp. purchases Dose Medical Corp. /iDose Product Line from DOSE Medical Corp.

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onGlaukos Corp. issued USD Common Stock

Underwriter

Advised onGlaukos Corp. issued USD Common Stock

Underwriter

Advised onGlaukos Corp. issued USD Common Stock

Legal Advisor

Advised onGlaukos Corp. purchases Avedro, Inc.

Legal Advisor

Advised onGlaukos Corp. purchases Avedro, Inc.

Advisors & Consultants
Advisor

Senior Vice President, Strategy at Medtronic Plc

Advisor

Former Chief Financial Officer & Secretary at DOSE Medical Corp.

Clients

TO PROVIDE PATIENT CARE AT THE HIGHEST QUALITY, MOST TECHNOLOGICALLY ADVANCED AND CONSISTENT MULTIDISCIPLINARY CARE.

Key Stats and Financials As of 2020
Market Capitalization
$2.65B
Total Enterprise Value
$3.22B
Earnings Per Share
$-2.7
Revenue
$225M
Net Profit
$-120M
Enterprise Value / Sales
14.3x
TEVNet Income
-26.73x
Debt TEV
0.08x
Total Equity
$667M
Total Debt
$272M
EBITDA
$-88.9M
EBITDAMargin
-39.54%
Three Year Compounded Annual Growth Rate Of Revenue
12.2%
Investors
Details Hidden

InterWest Partners focuses on early-stage investments in life sciences and information technology companies. Within the life sciences sector, the firm invests in a range of early-stage opportunities including the funding of preclinical companies with great potential. They also consider investing in or starting new companies around clinical or commercial stage assets. Within the information technology sector, InterWest looks for early-stage companies with near-term ROI-based value propositions. They favor investments in development-stage companies. Investments average $10 million to $15 million over the life of a company. InterWest serves as the lead investor in the majority of their investments.

Details Hidden

Former Senior Professional at Kraft

Details Hidden

Hans W. Liepmann Professor of Aeronautics & Bioinspired Engineering, Booth-Kresa Leadership Chair, Center for Autonomous Systems & Technologies, Director, Graduate Aerospace Laboratories & Director, Center for Autonomous Systems & Technologies at California Institute of Technology

Suppliers
D. Western Therapeutics Institute, Inc. Pharmaceuticals | Nagoya, Japan

D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. Its products include ophthalmic solution and agents for anti-platelet and anti-glaucoma. Its research and development laboratory undertakes drug design, screening of compounds, and selection of prospect compounds at early stage of drug research and development process. The company was founded by Hiroyoshi Hidaka on February 26, 1999 and is headquartered in Nagoya, Japan.

Santen Pharmaceutical Co., Ltd. Hospitals & Patient Services | Osaka, Japan

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

AbbVie, Inc. Pharmaceuticals - North Chicago, IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Glaukos Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Glaukos Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Glaukos Corp..